Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2020-06-29 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Dividend
Regulatory Filings
2020-06-29 English
Financial Result Updates
Regulatory Filings
2020-06-26 English
Updates
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Glenmark Pharmaceuticals Limited dated June 20, 2020, about their development and approval of Favipiravir as a treatment for mild to moderate COVID-19 in India. It includes company overview, global and Indian COVID-19 situation, clinical trial data, regulatory approval process, drug mechanism, dosage, and pricing. The document is structured as a slide presentation with extensive information aimed at informing stakeholders about the product launch and its significance. There is no indication that this is a regulatory filing, earnings release, or financial report. The document is clearly a detailed presentation intended for investors or the public to communicate the company's strategic development and product launch. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (over 14,000 characters) and content confirm it is the full presentation, not just an announcement or summary.
2020-06-20 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release dated June 20, 2020, announcing that Glenmark Pharmaceuticals has received regulatory approval for the oral antiviral Favipiravir for treatment of mild to moderate COVID-19. It is addressed to stock exchanges and includes a media release with detailed information about the drug, its approval, clinical trial results, and company comments. The document is a public announcement of a significant corporate development related to product approval and marketing, not a financial report, regulatory filing, or management report. It does not contain financial statements, voting results, or governance information. The content and format clearly identify it as a Capital/Financing Update (CAP) type document, as it relates to a major product approval and market launch impacting the company's business and capital prospects. The document length (7346 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2020-06-20 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) informing them about the approval from the Indian drug regulator for Glenmark Pharmaceuticals to manufacture and market Favipiravir for COVID-19 treatment. It is an announcement of a regulatory approval related to the company's product, not a financial report or detailed corporate filing. The document is short (2371 characters) and serves as an informational notice to the exchanges. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-06-19 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval for a specific drug (Fingolimod Capsules, 0.5 mg) from the U.S. FDA. It is addressed to stock exchanges and includes a request to take the announcement on record. The content is a media release about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is 3548 characters, which is relatively short and typical for an announcement. There is no financial data, no detailed report, or regulatory filing beyond the announcement itself. Therefore, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-06-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.